Sean M. Murphy, PhD

Professor of Population Health Sciences

Comparative Effectiveness and Outcomes (Population Health Sciences)

Contact & profiles

smm2010@med.cornell.edu

Appointments

Professor of Population Health SciencesPrimary
Population Health Sciences · 2023–
Professor
Weill Cornell Graduate School — Population Health Sciences · 2024–

Past Appointments

Associate Professor of Population Health Sciences
Population Health Sciences · 2020–2023
Associate Professor of Healthcare Policy and Research
Population Health Sciences · 2020–2020
Associate Professor of Research in Healthcare Policy and Research
Population Health Sciences · 2017–2019

Centers

Education

Ph.D., Economics
Washington State University, 2008
M.A., Economics
University of Montana, 2003
B.A., Economics
University of Montana, 2001

Highlights

1
Drug and alcohol dependence · 2020
SMSean M. Murphy
PMID: 33183909PMCID: PMC7737485DOIFirst and senior author60 citations
2
Journal of substance use and addiction treatment · 2023
SMSean M. Murphy
PMID: 36880906PMCID: PMC10084043DOISenior author19 citations
3
Psychiatric services (Washington, D.C.) · 2023
AJAli Jalali SMSean M. Murphy
PMID: 37337675PMCID: PMC10730760DOISenior author9 citations

Publications

151

Funding

43 View NIH portfolio on RePORTER ↗

Active

23 grants

Sub-PI
NIDA CTN-0155: Low-threshold Buprenorphine Treatment at Syringe Services Programs: a Type I Hybrid Effectiveness-implementation Trial
National Institute on Drug Abuse · 2019–2032 · via New York University· 6 renewals
UG1DA013035-25
Sub-PI
The Ohio Valley Node of the Clinical Trials Network - MOMs Project
National Institute on Drug Abuse · 2019–2032 · via University of Cincinnati· 3 renewals
UG1DA013732-26
Co-I
Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation
National Institute on Drug Abuse · 2017–2030· 4 renewals
P30DA040500-11A1
Sub-PI
Massachusetts HIV and Justice-Involved Populations Research Network
National Institute on Drug Abuse · 2024–2029 · via Boston Medical Center (Corporation)· 2 renewals
R61DA060588-02
Sub-PI
Peer Behavioral Activation Utilization to Address Structural Racism and Discrimination and Improve HIV Outcomes in High-Risk, Substance-Using Populations (PUSH)
National Institute on Drug Abuse · 2024–2029 · via University of Maryland, Baltimore
R01DA061324-03
Sub-PI
Assessing the Clinical and Cost-Effectiveness of a Virtual PEth-based Contingency Management for Adults with AUD
National Institute on Alcohol Abuse and Alcoholism · 2023–2028 · via Washington State University
R01AA031013-04
MPI
Researching Effective Strategies To Prevent Opioid Death (RESPOND)
National Institute on Drug Abuse · 2018–2028 · via Boston Medical Center (Corporation)· 2 renewals
R01DA046527-09
Sub-PI
A Randomized Controlled Trial of sublingual versus extended-release buprenorphine with individuals leaving Carceral Settings access, quality, and spending
National Institute on Drug Abuse · 2023–2028 · via Friends Research Institute, Inc.
R01DA058674-03
MPI
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network - CTN0121
National Institute on Drug Abuse · 2015–2028 · via University of Miami· 3 renewals
UG1DA013720-27
Co-I
Leveraging social determinants via artificial intelligence and peer coaching to address racial disparities in primary care among people who use opioids
Agency for Healthcare Research and Quality · 2023–2027 · via Friends Research Institute, Inc.
R18HS029783-02
Sub-PI
Peer-Delivered, Behavioral Activation Intervention to Improve Polysubstance Use and Retention in Telemedicine Mobile OUD Treatment in an Underserved, Rural Area
National Institute on Drug Abuse · 2022–2027 · via University of Maryland
R01DA057443-05
Sub-PI
A Decentralized, Status neutral, Stakeholder-engaged, post-incarceration intervention for people with and at risk for HIV
National Institute on Drug Abuse · 2024–2027 · via Yeshiva University
R33DA060627-03
Sub-PI
Stepped care, peer-delivered intervention to improve ART adherence and SUD in primary care
National Institute on Drug Abuse · 2022–2027 · via University of Maryland
R01DA056102-05
PI
JCOIN Phase II Economic Research Resource Center
National Institute on Drug Abuse · 2025–2027
U24DA064506-02
Sub-PI
Facilitating Opioid Care Connections: System level strategies to improve use of MAT and movement through the opioid care cascade for defendants in a new Opioid Court system
National Institute on Drug Abuse · 2019–2027 · via Research Foundation for Mental Hygiene, Inc.· 2 renewals
UG1DA050071-06
Sub-PI
The Continuum of Care in Hospitalized patients with Opioid Use Disorder and Infectious Complications of Drug Use (CHOICE): Multi-center Clinical Trial
National Institutes of Health, Clinical Center · 2024–2026 · via University of Maryland
75N90023C00013
Sub-PI
Integrated Outpatient Treatment of Opioid Use Disorder and Injection-Related Infections
National Institute on Drug Abuse · 2020–2026 · via University of Kentucky
R01DA048892-04
Sub-PI
SOAR: Smartphones for Opioid Addiction Recovery
National Institute on Drug Abuse · 2021–2026 · via New York University
R01DA054220-05
Sub-PI
Massachusetts Justice Cooperative Opioid Innovation Network (JCOIN) Research Center
National Institute on Drug Abuse · 2019–2026 · via University of Massachusetts Amherst· 2 renewals
UG1DA050067-06
Co-I
The Economic Viability and Value of Implementing an Inpatient Addiction Consult Model in Public Hospital Systems for Patients with Opioid Use Disorder
National Institute on Drug Abuse · 2023–2026
R03DA057465-01
Sub-PI
A Randomized Controlled Trial of sublingual versus extended-release buprenorphine with individuals leaving Carceral Settings
National Institute on Drug Abuse · 2019–2026 · via Friends Research Institute, Inc.· 2 renewals
UG1DA050077-05
Sub-PI
Economic evaluation of scalable strategies to improve mental health among perinatal women: Non-specialist care delivered via telemedicine vs. specialist care delivered in-person
Patient-Centered Outcomes Research Institute · 2024–2026 · via University of North Carolina
A24-0812
Sub-PI
Greater Southern California Node of the Clinical Trials Network
National Institute on Drug Abuse · 2022–2026 · via University of California, Los Angeles· 2 renewals
UG1DA049435-06

Completed grants (20)

Co-I
Reducing Post-Hospital Mortality in HIV-Infected Adults in Tanzania
National Institute of Mental Health · 2018–2025
R01MH118107-01
Sub-PI
Using Implementation Interventions and Peer Recovery Support to Improve Opioid Treatment Outcomes in Community Supervision
National Institute on Drug Abuse · 2023–2025 · via Brown University
U01DA050442-05S1
Sub-PI
Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression
National Institute on Drug Abuse · 2023–2025 · via Friends Research Institute, Inc.
R01DA056287-02
Sub-PI
Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder
National Institute on Drug Abuse · 2022–2025 · via Friends Research Institute, Inc.
R01DA056888-03
Sub-PI
Health Systems Node of the NIDA Clinical Trials Network (CTN-0074)
National Institute on Drug Abuse · 2019–2025 · via Kaiser Foundation Research Institute· 2 renewals
UG1DA040314-10
Co-I
DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)
National Institute on Drug Abuse · 2019–2025
U01DA047408-01A1
PI
Health and Economic Outcomes of Treatment with Extended-Release Naltrexone Among Pre-Release Prisoners with Opioid Use Disorder
National Institute on Drug Abuse · 2019–2025
R01DA046721-04
MPI
Impact of Jail-Based Methadone on Overdose, Recidivism, HIV, and Health Outcomes and Costs in New York City, 2011-2017
National Institute on Drug Abuse · 2018–2024 · via New York University School of Medicine (Grossman)
R01DA045042-05
Sub-PI
MassHEAL - Reducing overdose deaths 40% (2019-2023)
National Institute on Drug Abuse · 2019–2024 · via Boston Medical Center (Corporation)
UM1DA049412-04
Sub-PI
Onsite Buprenorphine Inductions at Harm Reduction Agencies to Increase Treatment Engagement and Reduce HIV Risk
National Institute on Drug Abuse · 2017–2024 · via Yeshiva University
R01DA044878-03
Sub-PI
Novel EtG Based Contingency Management for Alcohol in the Severely Mentally Ill
National Institute on Alcohol Abuse and Alcoholism · 2017–2023 · via Washington State University
R01AA020248-08
PI
Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017
New York City Department of Health & Mental Hygiene · 2019–2023Contract
DUA 192260-01
Co-I
A pragmatic trial of two strategies for implementing an effective eHealth HIV prevention program
National Institute of Mental Health · 2018–2023 · via Northwestern University
R01MH118213-03
Sub-PI
CTN-0069 Implementation of ED-Initiated Buprenorphine for Opioid Use Disorder
National Institute on Drug Abuse · 2018–2022 · via Yale University· 2 renewals
UG1DA015831-20
Sub-PI
California SUD Service Delivery Evaluation - Cost Benefit Analyses
California Department of Health Services · 2021–2021 · via The Regents of the University of California
UCLA 220870-01
Sub-PI
California MAT Expansion Project
California Department of Health Services · 2019–2021 · via University of California, Los Angeles
UCLA 183373-01
Sub-PI
Improving Naloxone Access and Its Effects on Drug Abuse Overdoses
Centers for Disease Control and Prevention · 2019–2021 · via RAND Corporation
R01CE002999-03
Co-I
Economic Evaluation of Medication-Assisted Substance Abuse Treatment
National Institute on Drug Abuse · 2014–2020
R01DA035808-04
Sub-PI
Conduct Medication Assisted Treatment and Mental Health Specialized Docket Program Evaluation
Ohio Department of Mental Health and Addiction Services · 2018–2019 · via Public Health Management Corporation
PHMC 183301-01
KP
Supervised Injection Facility Feasibility Study
Fund for Public Health in New York, Inc. · 2017–2017Contract
FPHNY SA

Clinical research

Active

6 studies

PI
Economic Evaluation to Assess the Clinical and Cost-Effectiveness of a Virtual PEth-based Contingency Management for Adults with AUD
Washington State University · OPEN TO ACCRUAL (as of 2024)
PI
SOAR: Smartphones for Opioid Addiction Recovery
NYU Langone · OPEN TO ACCRUAL (as of 2022)
PI
Economic Analysis alongside CTN-0102: Rural Expansion of Medication Treatment for Opioid Use Disorder (Rural MOUD)
University of California, Los Angeles · OPEN TO ACCRUAL (as of 2021)
PI
Emergency Department-Initiated Buprenorphine Validation Network Trial
PHASE2 · Yale University · OPEN TO ACCRUAL (as of 2021)
Opioid-use Disorder
NCT04225598
PI
Economic Analysis alongside CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
National Institute on Drug Abuse · OPEN TO ACCRUAL (as of 2020)
PI
Friends Research Institute Justice Community Opioid Innovation Network (JCOIN-FRI)
Friends Research Institute, Inc. · OPEN TO ACCRUAL (as of 2020)

Completed & closed trials (7)

PI
Economic Evaluation on Medication treatment for Opioid use disorder in expectant Mothers (MOMs): a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations
University of Cincinnati · IRB STUDY CLOSURE (as of 2026)
PI
Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder
Friends Research Institute, Inc. · IRB STUDY CLOSURE (as of 2025)
PI
Economic Evaluation of CTN 0074: PRimary care Opioid Use Disorders Treatment (PROUD) Trial
Kaiser Foundation Health Plan of Washington · IRB STUDY CLOSURE (as of 2025)
PI
Economic Evaluation of Buprenorphine Integrated Outpatient Treatment of Opioid Use Disorder and Injection-Related Infections (B-OPAT)
University of Kentucky · CLOSED TO ACCRUAL (as of 2025)
PI
Comparative- and Cost-effectiveness Research Determining the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression (Text Me, Alexis!)
Friends Research Institute, Inc. · IRB STUDY CLOSURE (as of 2025)
PI
Massachusetts Justice Community Opioid Innovation Network (JCOIN) Clinical Research Center _x000D_ (MA-JCOIN)
Baystate Medical Center · CLOSED TO ACCRUAL (as of 2025)
PI
Economic Evaluation of implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH)
National Institute on Drug Abuse · CLOSED TO ACCRUAL (as of 2020)

News mentions

3 View all WCM news ↗

New Funding for Health Economics Research on Substance Use Disorder Treatments
October 30, 2025
A team led by Weill Cornell Medicine and University of Miami’s Miller School of Medicine investigators has been awarded a five-year, $4 million grant from the National Institute on Drug Abuse (NIDA) for health economics research.
Improving Care of Hospitalized Patients with HIV in Tanzania
March 11, 2024
Researchers at Weill Cornell Medicine have shown that three months of social worker follow-up support to people hospitalized with HIV in Tanzania had health benefits at low cost.
In Brief: People with Drug Use Disorders May be Foregoing Care During Pandemic
December 29, 2020
Fear of COVID-19 and changes to healthcare delivery during the pandemic may be causing people with substance use disorders to avoid seeking any type of care and thus less likely to get treatment for addiction.

Mentoring

3 All publications with mentees →